Bond University Opens a PhD Pathway on Medicine Pricing Across the PBS Lifecycle

The Pharmaceutical Benefits Scheme (PBS) spent $17.7 billion of Commonwealth money in 2023–24 to subsidise 930 different medicines across 5,164 brands. That is the visible half of Australia's medicines spending. The invisible half is what happens after a medicine is listed: the price gets quietly corrected by rebates, statutory reductions and twice-a-year disclosure cycles, while the clinical evidence that justified the original price keeps moving.

Bond University is now advertising an expression of interest (EOI) for a PhD student to study exactly that second half. The project, on the lifecycle value and pricing of medicines on the Australian PBS, sits inside a new National Health and Medical Research Council (NHMRC) Centre of Research Excellence (CRE) led by Professor Stephen Goodall of the University of Technology Sydney and supervised locally by Associate Professor Hansoo Kim. For a domestic student who fits the bill, it comes with an NHMRC-funded living stipend for three years, a Research Training Program (RTP) tuition fee waiver and the possibility of tutoring or research assistant work.

Nobody designed the timing by accident. Australia's 2024 Health Technology Assessment (HTA) Policy and Methods Review recommended more formal attention to post-HTA evidence, pricing and reassessment over a medicine's lifecycle. This doctoral project is one of the first candidates trained on that recommendation while the policy window is still open.

The price on the sticker is only half the story

Here is the thing nobody tells you about the PBS Schedule. The number printed next to a medicine, the approved ex-manufacturer price, is rarely what the Commonwealth actually ends up paying. A medicine only gets listed after the Pharmaceutical Benefits Advisory Committee (PBAC, the body that weighs clinical effectiveness, safety and cost-effectiveness) says it is worth subsidising, and the price that follows is the opening line of a negotiation. The real number often lives inside a rebate or a risk-sharing deed the public never sees.

Then the machinery starts. When a competing generic or biosimilar brand arrives, a statutory price reduction kicks in. Single-brand medicines face automatic reductions at set anniversaries. Once multiple brands compete, price disclosure takes over: sponsors report their actual discounted selling prices every six months, and the listed price is pulled toward the weighted average of what pharmacies really pay, the weighted average disclosed price or WADP. So the sticker keeps changing.

The other half of the problem is that a medicine's value can move in two directions at once. A cancer drug listed on immature survival data may look better, or worse, once longer follow-up arrives, and its comparator may have gone generic in the meantime. Nobody routinely goes back to check whether the original price still matches the current evidence. That question is the point of the Bond project.

The PhD sits within the Australian Network of Health Technologies Assessment Methods (ANTHEM), a new NHMRC Centre of Research Excellence funded with $3 million over five years. According to the UTS announcement of the centre, health technology assessment was built for cheap drugs tested in huge populations, and Australia now has to fund treatments aimed at smaller groups with higher prices and less mature evidence. ANTHEM's four research streams, covering faster access, fairer access, transparency with patient involvement and future-ready methods, give the Bond doctoral project a ready-made national audience.

The successful candidate will spend the doctorate on four overlapping jobs: scoping and systematic evidence reviews of post-listing reassessment approaches in Australia and overseas; longitudinal analyses of PBS pricing, utilisation and reimbursement data, the unglamorous spreadsheet work that shows whether prices and prescribing are drifting apart; stakeholder surveys and expert consensus processes to work out when and how a medicine's price should be revisited; and health economic models that test alternative lifecycle pricing approaches against cost-effectiveness, system value and pharmaceutical expenditure.

Supervision by Associate Professor Hansoo Kim tells you the flavour of the work. Kim has published on generic price erosion in the Australian market and on statin pricing under PBS price disclosure. A 2021 cost-effectiveness reassessment of nivolumab for renal cell carcinoma, co-authored with Kim, found the drug needed a 54 per cent rebate to reach the accepted threshold once mature survival data and a cheaper comparator price were factored in. Same medicine, updated evidence, very different answer, lifecycle reassessment in miniature.

The policy hook is the final report of the 2024 Health Technology Assessment Policy and Methods Review, published in September 2024. Of its 50 recommendations, the relevant ones point in one direction: publish a clearer post-HTA pricing, negotiation and listing framework; allow flexible contract and funding mechanisms; support periodic examination of how a listed technology performs and where it sits clinically; and lean on managed entry agreements and real-world data to handle uncertainty that no one can resolve at the first decision. Recommendation 17, the pricing offer framework, is the policy cousin of what the Bond PhD proposes to study.

As of early 2025 the Government had not yet formally responded to the report, according to Rare Cancers Australia's briefing, which means the doctoral project will run while the policy window is still open, likely to be read by people who can act on it. International comparators have moved too: Canada's Drug and Health Technology Agency has piloted an expert committee on decisions across the drug life cycle, and England's NICE has tested pathways pilots for re-evaluating existing recommendations. Australia is not inventing this from nothing; it is, characteristically, waiting for the evidence before it commits.

The scale is the first reason to care. In 2023–24, according to the Department of Health and Aged Care's expenditure and prescriptions report, concessional patients received 199 million subsidised scripts and general patients another 27.1 million. Patients contributed $1.6 billion toward the cost of their medicines; the Commonwealth covered $17.7 billion, or 91.6 per cent of the total. The average government contribution was $54.34 for a concessional script and $250.60 for a general patient script. Those numbers explain why the co-payment freeze at $31.60 for general patients, and $7.70 for concession cardholders, was sold as cost-of-living relief, and why the Government's half of the transaction is where most of the savings live.

The second reason is that the existing pricing machinery works, just unevenly. A study of tumour necrosis factor inhibitor biosimilars estimated savings to the PBS of roughly AU$562 million between 2015 and 2025 after adalimumab, etanercept and infliximab biosimilars were listed. A separate analysis of statins found annual PBS statin expenditure fell by AU$833.5 million, or 83 per cent, between 2010 and 2022 while prescriptions fell 15.7 per cent. The sticker kept being corrected, and the corrections added up to real money.

What is missing is a planned way to ask a harder question once a medicine gets cheaper: does the price still reflect what the medicine now does for the people using it? The Bond project is positioned exactly there, as reviewer, modeller and occasional consensus facilitator, three hats that rarely fit on the same day.

The eligibility bar is honest. You need an Honours degree at Class 1 or Class 2 Division A, a Masters by Research, or a Masters with a substantial research component, or equivalent research experience, which in practice means a research assistant role, publications or professional research work that show you understand methodology. The essential degree list is deliberately broad: health sciences, pharmacy, economics, public health, epidemiology, statistics or data science all count. So does an interest in health policy and research translation, the polite way of saying you do not mind your findings being debated by people who disagree with you.

Desirable experience reads like a job ad for the work itself: health economics, health technology assessment, economic evaluation, outcomes research, statistical software, and comfort with large pharmaceutical or administrative datasets. If you have already worked on PBS data, a payer submission or a pharmacy-side pricing question, you will find the first six months considerably less bewildering than the rest of us did.

Funding is standard for an NHMRC-linked doctoral post: a tuition fee waiver under the Research Training Program for eligible Australian and New Zealand citizens and Australian permanent residents, plus a living stipend for up to three years, plus the possibility of tutoring or research assistant work within the Faculty of Health Sciences and Medicine. The tutoring and RA work is not a perk; it is how many research candidates learn to explain health economics to people who would rather be doing something else. Our guide on thriving as a research assistant in Australia covers the part nobody puts in the job ad.

Applications go through Bond University's portal, not through a funding body. The EOI must include the position title, a two-page statement on why this project and what you would want to research, a two-page response to the selection criteria, a current CV with two academic referees, academic transcripts and a sample of your academic writing, an Honours thesis, a journal article or a research project will do. The deadline for this round is 4 December 2026. The full ad, with the exact wording, is on Bond University's jobs page.

Nobody tells you this when you are applying for a project like this: the two-page interest statement is not an essay about how much you love medicines policy. It is an argument in miniature. Here is the question I would ask, here is the data I would need, here is what I already know, here is what the reviewers should conclude. The selection criteria response, on the other hand, is a matching exercise in plain English. If a criterion says 'demonstrated quantitative and analytical skills,' do not write 'I am passionate about numbers.' Write 'I cleaned a 400,000-row prescribing dataset for my Honours project and ran fixed-effects models in Stata.' The referees and the writing sample do the persuasion; your two pages just need to prove you understand the brief. Our guide to writing an academic CV that gets read will help with the framing.

The candidate who lands this will do their doctorate in a strange window, where national policy direction has been publicly identified but not yet legislated, and where the evidence they produce can still shape the design rather than merely justify it. That is rare in health services research, where the usual rhythm is study something for four years, publish, and hope the policy has not moved three times. Here the policy is the runway.

For Australian pharmacists, health economists, data scientists and public health graduates who find PBS pricing data genuinely interesting, the door is open on the Gold Coast. The project will generate publications and policy-relevant outputs, and the skills, HTA, economic modelling, real-world data analysis, stakeholder facilitation, transfer directly to government pricing sections, payer organisations, the medicines industry and academic units. Apply through the portal. The bargain, as with every good PhD, is that you will never again read the price on the sticker without asking what it actually cost.